Gujarat Kidney & Super Speciality Ltd (GKSL)

Healthcare · Healthcare · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹162.4

🎯 Key Takeaways

Gujarat Kidney & Super Speciality Ltd (GKSL) is transitioning from a micro-cap healthcare player to a more institutionalized entity, marked by governance upgrades and investor engagement. The company operates in a niche segment of kidney care and super-speciality services, with financial metrics indicating high profitability but a valuation premium reflected in a 66 P/E ratio.
Revenue grew 12.1% QoQ to ₹34 in Q1FY27.
⚠️ The unaudited financials lack full audit verification, raising concerns about data reliability despite no material misstatements being flagged.

Market Cap

₹1,280

P/E Ratio

66.0

P/B Ratio

49.36

ROE

64.5%

ROCE

77.4%

Debt/Equity

0.15

Promoter

71.5%

✨ Ask AI About GKSL 📊 Interactive Charts

📖 The Story

Gujarat Kidney & Super Speciality Ltd (GKSL) is transitioning from a micro-cap healthcare player to a more institutionalized entity, marked by governance upgrades and investor engagement. The company operates in a niche segment of kidney care and super-speciality services, with financial metrics indicating high profitability but a valuation premium reflected in a 66 P/E ratio. Recent board actions and regulatory filings suggest a deliberate effort to strengthen corporate governance and transparency, positioning it for broader investor acceptance.

📰 What's Happening

In Q1 FY2026, GKSL filed unaudited standalone and consolidated financial results with SEBI-mandated disclosures, confirming no material misstatements but limited auditor assurance. The company appointed Dr. Disha Bharpoda as an Additional Non-Executive Independent Director effective August 24, 2026, pending shareholder ratification at the upcoming AGM. It also issued a pre-advertisement notice for the 7th AGM scheduled for September 28, 2026, and participated in a GIA Healthcare Day investor meeting on August 31, 2026, to enhance market visibility. These actions reflect a strategic focus on governance, stakeholder engagement, and long-term institutional credibility.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	15	13	23	31	34
Operating Profit	8	4	6	5	7
OPM %	50.3%	32.6%	23.9%	15.7%	20.2%
Net Profit	5	3	4	5	5
EPS	₹1.00	₹0.47	₹0.52	₹0.81	₹0.66

Revenue has shown a sharp upward trend, rising from ₹15 crore in Q1 FY2025 to ₹34 crore in Q1 FY2026, doubling year-on-year, with operating profit and net profit also doubling during the same period. However, operating margins have declined from 50.3% to 20.2%, indicating scaling challenges or pricing pressures despite revenue growth. Net profit margin remains stable around 15%, supported by cost control, but EPS has stabilized at ₹0.66. The financial trajectory reflects rapid top-line expansion, but sustainability depends on maintaining margins amid rising operational scale.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue or profitability in the reviewed filings. However, the appointment of an independent director and engagement in investor forums suggest a focus on transparency and governance rather than aggressive growth guidance. The variation in IPO fund usage has been shareholder-approved, indicating capital structure flexibility, but no roadmap for deployment has been disclosed. Management appears to be prioritizing structural readiness over near-term expansion targets.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2026	Mar 2026
Equity Capital	11	11	16
Reserves	15	22	237
Borrowings	4	20	29
Total Liabilities	55	76	298
Fixed Assets	31	22	38
Investments	0	0	0
Total Assets	55	76	298

The balance sheet shows a strong equity base of ₹16 crore with reserves of ₹237 crore as of March 2026, up from ₹11 crore equity and ₹22 crore reserves in the prior year, reflecting accumulated surpluses. Borrowings remain minimal at ₹29 crore, indicating a conservative capital structure with negligible debt. Total assets have grown from ₹55 crore to ₹298 crore over two years, signaling significant asset base expansion, likely from operational scaling. The company is not leveraging debt for growth, suggesting a self-funded or internally financed trajectory.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+14
Investing	-18
Financing	+6
Net Cash Flow	+2

👥 Shareholding Pattern

Category	Q4FY25	Q3FY26	Q4FY26	Q1FY27
Promoters	99.1%	71.5%	71.5%	71.5%
FII	0.0%	10.5%	4.9%	4.9%
DII	0.0%	1.7%	0.6%	0.6%
Public	0.0%	11.6%	10.6%	10.6%
# Shareholders	7	27,783	18,301	18,301

Promoter holding remains stable at 71.45% across recent quarters, indicating no dilution or exit. However, FII allocation has declined from 10.47% in Q3 FY26 to 4.88% in Q4 FY26 and Q1 FY27, while DII rose slightly to 0.56%. The sharp drop in FII participation may reflect reduced institutional interest or re-rating due to governance or scale concerns. The increase in public shareholders from 7 to 27,783 suggests retail broadening, but institutional confidence appears to be waning, possibly due to limited transparency or scale perception.

⚖️ Peer Comparison — Healthcare

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
APOLLOHOSP	1.26 L Cr	60.3	22.1%	22.9%	0.60
MANIPALHOS	98,259	—	—	—	1.25
MAXHEALTH	98,006	67.2	14.4%	13.6%	0.27
FORTIS	68,769	65.6	13.3%	10.8%	0.29
ASTERDM	66,090	122.7	17.2%	11.9%	0.21
NH	39,605	48.2	13.7%	18.0%	1.07
MEDANTA	39,163	70.4	21.9%	16.3%	0.10
LALPATHLAB	31,910	45.9	29.6%	21.8%	0.00
KIMS	31,878	148.8	9.7%	8.7%	1.44
POLYMED	17,790	56.5	15.1%	11.3%	0.06

🔗 Peer Stock Analyses

APOLLOHOSP MANIPALHOS MAXHEALTH FORTIS ASTERDM

⚠️ Risk Factors

1. The unaudited financials lack full audit verification, raising concerns about data reliability despite no material misstatements being flagged. 2. Operating margins have declined sharply despite revenue growth, suggesting potential scalability or pricing challenges not addressed in filings. 3. Institutional investor interest is weakening, with FII allocation halving in recent quarters, which could impact liquidity and valuation. 4. The company's growth trajectory relies heavily on unaudited metrics and limited disclosures, creating uncertainty around true financial health and sustainability.

📋 Recent Filings

🧠 Analyst's Read

GKSL is undergoing a governance and scale transition, but its financial narrative remains constrained by limited transparency and declining institutional interest. The company must address margin sustainability and improve disclosure rigor to gain investor confidence. The next catalyst will be the AGM outcome and potential clarity on IPO fund usage, but until then, the investment case hinges on execution quality and management credibility rather than financial momentum alone.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on GKSL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GKSL files new disclosures

Track GKSL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GKSL — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd